Tallac Therapeutics selects Dr. Kevin Heller as chief medical officer

Kevin Heller, MD, has been named chief medical officer of Tallac Therapeutics, a biopharmaceutical company using innate and adaptive immunity to fight cancer.

Advertisement

Dr. Heller joins Tallac from Jasper Therapeutics, where he served as executive vice president of research and development. Prior to that, he was the chief medical officer for NextCure, according to a Jan. 19 release.

Dr. Heller got his start in the biopharmaceutical industry at Bristol Myers Squibb, where he eventually became global lead for oncology search and evaluation. He went on to serve as senior medical director for AstraZeneca and vice president and head of antibody clinical development at Incyte.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Leadership

Advertisement

Comments are closed.